What is the recommended first‑line therapy and overall management for cerebral malaria?

Cerebral Malaria: First-Line Therapy and Management

For cerebral malaria, intravenous artesunate is the definitive first-line antimalarial treatment, with parenteral quinine as an alternative when artesunate is unavailable. 1, 2

Immediate Resuscitation and Stabilization

Airway, breathing, and circulation take absolute priority before antimalarial therapy:

• Administer high-flow oxygen immediately to all patients with impaired consciousness 3
• Check blood glucose urgently and correct hypoglycemia (if <3 mmol/L) with 5 ml/kg of 10% dextrose 3
• Elective intubation and mechanical ventilation are indicated for patients with Glasgow Coma Scale ≤8 or features suggesting raised intracranial pressure 3
• Establish vascular or intraosseous access for medication administration and fluid resuscitation 3

Antimalarial Treatment

Parenteral Therapy

Intravenous artesunate is superior to quinine and reduces mortality in severe malaria 1, 2:

• Administer at least 3 doses of IV artesunate initially 1
• Monitor parasitemia every 12 hours until <1%, then every 24 hours until negative 1
• Transition to oral artemisinin-based combination therapy (ACT) when parasitemia drops below 1% and oral intake is feasible 1

If artesunate is unavailable, use quinine hydrochloride 3:

• Loading dose: 20 mg salt/kg IV over 4 hours (critical for rapid parasite clearance) 3
• Maintenance: 10 mg/kg IV over 4 hours, every 8 hours 3
• Omit loading dose if patient received mefloquine prophylaxis in previous 24 hours or treatment dose within 3 days 3
• Continue for 7 days or switch to oral ACT when tolerated 3

Important Caveat

Peripheral parasitemia may not decrease—and may even increase—during the first 24 hours of quinine treatment due to its mechanism of action; this does not indicate treatment failure in African cases 3

Seizure Management

Seizures occur commonly in cerebral malaria (25% may be subtle or subclinical, manifesting as eye deviation, irregular breathing, or drooling) 3:

• First-line: Lorazepam 0.1 mg/kg IV/IO, may repeat once after 10 minutes 3
• Second-line: Paraldehyde 0.4 mg/kg rectally (0.8 ml/kg of prepared solution) 3
• Third-line: Phenytoin 18 mg/kg IV over 20 minutes OR Phenobarbital 15-20 mg/kg IV over 10 minutes 3
• If seizures persist: Call anesthetist for rapid sequence intubation with thiopental 4 mg/kg 3

Critical warning: Prophylactic phenobarbital (20 mg/kg IM) increased mortality in Kenyan children with cerebral malaria, particularly when combined with diazepam, likely due to respiratory depression in unventilated patients 3. Therefore, seizure prophylaxis is NOT recommended 3.

Raised Intracranial Pressure Management

Brain swelling is a major feature in fatal cerebral malaria cases 3:

Recognition

• Unilateral sluggish or absent pupillary responses are the only reliable signs of raised ICP 3
• Declining consciousness, focal neurology, abnormal posturing, papilledema, hypertension with bradycardia are late findings 3
• Exercise caution in peri-ictal states where pupillary signs may be misleading 3

Treatment

• Rapid induction of anesthesia, intubation, and mechanical ventilation when raised ICP is suspected 3
• Maintain PCO2 in normal range (no evidence that hyperventilation benefits raised ICP in malaria) 3
• Mannitol 0.5 mg/kg IV over 5-10 minutes may lower ICP temporarily; repeated doses often necessary 3
• Steroids are NOT recommended (unclear effect on ICP and may worsen outcomes) 3

Metabolic and Supportive Management

Very Common Complications

• Hypoglycemia (glucose <3 mmol/L): Use maintenance fluids with 5-10% glucose for prevention 3
• Hyperpyrexia: Treat with antipyretics or tepid sponging; ibuprofen is superior to paracetamol for fever reduction (reduce dose in renal impairment) 3

Electrolyte Corrections (Table 2 from guidelines) 3:

• Potassium <3.5 mmol/L: 0.25 mmol/kg over 30 minutes
• Total calcium <2 mmol/L: 0.3 ml/kg of 10% calcium gluconate over 30 minutes
• Magnesium <0.75 mmol/L: 0.2 ml/kg of 50% MgSO4 over 30 minutes
• Phosphate <0.7 mmol/L: 0.2 mmol/kg of NaPO4 over 30 minutes

Monitoring Requirements

Daily monitoring should include 1:

• Full blood count
• Hepatic and renal function tests
• Glycemia and blood gas analysis
• Monitor for delayed hemolysis on days 7,14,21, and 28 post-artesunate treatment 1

Adjunctive Therapies: Current Evidence

No adjunctive therapies have demonstrated benefit in reducing mortality or improving outcomes in cerebral malaria 3, 4, 5. Multiple interventions including N-acetylcysteine, mannitol (beyond acute ICP management), measures to increase nitric oxide, and various neuroprotective agents have failed to show consistent benefit 4, 5, 6. The focus must remain on rapid antimalarial treatment and meticulous supportive care 2, 4.

Special Populations

Pregnant women and children should receive IV artesunate according to current US guidelines 2. The mortality from cerebral malaria remains 15-20% even with optimal treatment, and substantial neurocognitive sequelae occur in survivors 7, 6, 8, 9.